PDLIM7 and nasopharyngeal carcinoma: Similar strategies for ACT have been developed for patients with NPC and HL, where CTLs specific to EBV latent antigens (e.g. EBNA1, LMP1, LMP2) are expanded ex vivo and infused into patients (304).